No Data
No Data
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Maxim Group analyst Jason McCarthy maintains $VistaGen Therapeutics(VTGN.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 23.
Buy Rating Affirmed on VistaGen Therapeutics Amid Strong Financials and Promising Clinical Trials
Earnings Call Summary | VistaGen Therapeutics(VTGN.US) Q1 2025 Earnings Conference
VistaGen Therapeutics | 10-Q: Q1 2025 Earnings Report